Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 9, Issue 1, 2015, Pages 30-33

  Kesavadev, Jothydev ^a   Shankar, Arun ^a   Gopalakrishnan, Gopikakrishnan ^a   Jothydev, Sunitha ^a  

^a Jothydev's Diabetes and Research Center   (India)

Author keywords

Diabetes; India; Liraglutide; Type 2

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; ISOPHANE INSULIN; LIRAGLUTIDE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FLATULENCE; GASTRITIS; GLUCOSE BLOOD LEVEL; HUMAN; INDIAN; INSULIN PUMP; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOTION SICKNESS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STUDENT T TEST; VOMITING; ANALOGS AND DERIVATIVES; BLOOD; CAUCASIAN; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG EFFECTS; EXERCISE; INDIA; LOW CALORY DIET; METABOLISM; PROCEDURES; TREATMENT OUTCOME; WEIGHT REDUCTION;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIET, REDUCING; DRUG ADMINISTRATION SCHEDULE; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXERCISE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INDIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84920735336     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2014.04.034     Document Type: Article

References (15)

1. D.R. Whiting, L. Guariguata, C. Weil, and J. Shaw IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030 Diabetes Res Clin Pract 94 3 2011 311 321
2. R.M. Anjana, R. Pradeepa, M. Deepa, M. Datta, V. Sudha, and R. Unnikrishnan Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study Diabetologia 54 12 2011 3022 3027
3. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, and M. Nauck Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 6 2012 1364 1379
4. I.M. Stratton, A.I. Adler, H.A. Neil, D.R. Matthews, S.E. Manley, and CullCA Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study Br Med J 321 7258 2000 405 412
5. Highlights of prescribing information, Victoza® (liraglutide [rDNA origin] injection), available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022341s007s009s013lbl.pdf [accessed 17.09.12].
6. J. Kesavadev, A. Shankar, P.B. Pillai, G. Krishnan, and S. Jothydev Cost-effective use of telemedicine and self-monitoring of blood glucose via Diabetes Tele Management System (DTMS) to achieve target glycosylated hemoglobin values without serious symptomatic hypoglycemia in 1000 subjects with type 2 diabetes mellitus - a retrospective study Diabetes Technol Ther 14 9 2012 772 776
7. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 9131 1998 854 865
8. R.R. Holman, S.K. Paul, Bethel MA, D.R. Matthews, and H.A. Neil 10-Year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 15 2008 1577 1589
9. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 14 1993 977 986
10. D.M. Nathan, P.A. Cleary, J.Y. Backlund, S.M. Genuth, J.M. Lachin, and T.J. Orchard Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 353 25 2005 2643 2653
11. H.C. Gerstein, M.E. Miller, R.P. Byington, D.C. Goff Jr., J.T. Bigger, and J.B. Buse Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 24 2008 2545 2559
12. A. Patel, S. MacMahon, J. Chalmers, B. Neal, L. Billot, and M. Woodward Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 24 2008 2560 2572
13. W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emanuele, and P.D. Reaven Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2 2009 129 139
14. J. Kesavadev, A. Shankar, G. Krishnan, and S. Jothydev Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting Int J Gen Med 5 2012 317 322
15. B.N. Mercer, S. Morais, R.M. Cubbon, and M.T. Kearney Diabetes mellitus and the heart Int J Clin Pract 66 7 2012 640 647